



PRECIRIX®

Precision radiopharmaceuticals technology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. Precirix' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.

When ambition meets ambition

The PRECIRIX® team has a renowned expertise in radio-immunotherapy and is well positioned to move up to the next level. This investment clearly fits into our Health & Care strategy and, with a platform portfolio of about 20 companies, underpins our position as one of the most active European investors in the healthcare industry.

Together, we build a leading company

With this financing, which is one of the larger rounds of a European early-stage life sciences company, PRECIRIX® will be able to run a phase Ib/II trial with its lead program targeting brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline. We are delighted that we can contribute to this lead program thanks to our expertise through earlier investments in life sciences companies.

Summary

Activity	Precision radiopharmaceuticals for cancer treatment
Location	Belgium
Entry	2018
Platform	Life Sciences
Website	www.precirix.com

